| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/05/2013 | CN102049038B Application of gelatinase A inhibitory polypeptide modifier |
| 06/05/2013 | CN101993496B Dual blood sugar and blood fat adjusting fusion protein and preparation method and application thereof |
| 06/05/2013 | CN101969975B Chimeric HIV fusion proteins as vaccines |
| 06/05/2013 | CN101906152B Stx2 inhibitor peptide and vero toxin-neutralizing agent |
| 06/05/2013 | CN101905015B Medicine capable of decomposing alcohol, preventing drunkenness and protecting liver |
| 06/05/2013 | CN101883781B 7P peptide and its derivant, the use thereof |
| 06/05/2013 | CN101873865B Use of the sequence encoding the carboxyl-terminal domain of the heavy chain of tetanus toxin as a drug |
| 06/05/2013 | CN101863964B Helicobacter pylori urease B antigen epitope polypeptide and application thereof |
| 06/05/2013 | CN101810561B Hirudin polyion micelle composition |
| 06/05/2013 | CN101678106B Combination of Blys inhibition and/or APRIL inhibition and immunnosuppressants for treatment of autoimmune disease |
| 06/05/2013 | CN101654672B RNA interference mediating small RNA molecules |
| 06/05/2013 | CN101596308B ITGB4BP and derivates thereof used for preventing and/or treating hypertrophic scar and fibrosis lesion |
| 06/05/2013 | CN101541341B Analogs of ghrelin substituted at the N-terminal |
| 06/05/2013 | CN101522186B Methods, compositions and articles of manufacture for contributing to the treatment of cancers |
| 06/05/2013 | CN101501209B A method of producing biologically active polypeptide having insulinotropic activity |
| 06/05/2013 | CN101460624B Sense oligonucleotide capable of controlling the expression of iNOS and composition comprising the same |
| 06/05/2013 | CN101260398B Nerve growth factor gene positioning reconstruction animal and its preparation method and application |
| 06/05/2013 | CN101031583B Antimicrobial peptides containing arginine and/or lysine motif |
| 06/04/2013 | US8455652 Inhibitors for the soluble epoxide hydrolase |
| 06/04/2013 | US8455618 Melanocortin receptor-specific peptides |
| 06/04/2013 | US8455617 Melanocortin receptor-specific peptides |
| 06/04/2013 | US8455616 Nuclear translocation peptide |
| 06/04/2013 | US8455614 PMMA binding peptides |
| 06/04/2013 | US8455538 Augmented cognitive training |
| 06/04/2013 | US8455490 Facially amphiphilic polymers and oligomers and uses thereof |
| 06/04/2013 | US8455453 Use of VEGF-D gene to prevent restenosis |
| 06/04/2013 | US8455450 Methods for obtaining a therapeutically effective amount of hematopoietic precursor cells and long term engraftment thereof |
| 06/04/2013 | US8455449 Compositions and methods for modulating γ-c-cytokine activity |
| 06/04/2013 | US8455448 Myostatin isoform |
| 06/04/2013 | US8455447 Modified therapeutic agents |
| 06/04/2013 | US8455446 Single domain TDF-related compounds and analogs thereof for use in treating a tissue differentiation factor related disorder |
| 06/04/2013 | US8455445 Methods for inhibiting lymphotoxin-β receptor signaling in TH1 cell-associated disorders |
| 06/04/2013 | US8455444 CDH3 peptide and medicinal agent comprising the same |
| 06/04/2013 | US8455443 Methods of use of skin wound healing compositions |
| 06/04/2013 | US8455442 Peptides having binding affinity to an antibody which recognizes an epitope on an α1 loop 2 or β2 loop 1 of an adrenoreceptor |
| 06/04/2013 | US8455440 Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor |
| 06/04/2013 | US8455439 Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents |
| 06/04/2013 | US8455436 Compositions and methods for treating joints |
| 06/04/2013 | US8455435 Combination of granulocyte-colony stimulating factor (G-CSF) and DPP-IV inhibitors like Vildagliptin or Sitagliptin |
| 06/04/2013 | US8455434 Methods of use for cysteine variants of human G-CSF |
| 06/04/2013 | US8455433 Process for solubilizing glucagon-like peptide 1 compounds |
| 06/04/2013 | US8455432 Insulin sensitisers and methods of treatment |
| 06/04/2013 | US8455428 Activin-like receptor kinase immunoglobulin fusion for prevention and treatment of cell proliferative and vision defects; angiogenesis inhibitors |
| 06/04/2013 | US8455427 Methods of modifying insulin signaling using biliverdin reductase |
| 06/04/2013 | US8455235 Protease variants for pharmaceutical use |
| 06/04/2013 | US8455217 Nucleic acids encoding IL-17 homologous receptor-like polypeptides and therapeutic uses thereof |
| 06/04/2013 | US8455204 Brown adipocyte progenitors in human skeletal muscle and methods for identifying differentiation agents therefor |
| 06/04/2013 | US8455004 Primary composition comprising a lipophilic bioactive compound |
| 06/04/2013 | US8454978 Immunostimulating agent |
| 06/04/2013 | US8454976 Recombinant toxin fragments |
| 06/04/2013 | US8454975 Method for enhancing skin appearance |
| 06/04/2013 | US8454971 Glucagon/GLP-1 receptor co-agonists |
| 06/04/2013 | US8454968 Method for inducing immunity with a peptide fragment from human CAPRIN-1 |
| 06/04/2013 | US8454966 Nanoparticles for protein drug delivery |
| 06/04/2013 | US8454963 Tissue targeted complement modulators |
| 06/04/2013 | US8454960 Multispecific antibody targeting and multivalency through modular recognition domains |
| 06/04/2013 | US8454958 Methods for detecting and inhibiting angiogenesis |
| 06/04/2013 | US8454954 Treatment of synucleinopathies |
| 06/04/2013 | US8454951 Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women |
| 06/04/2013 | US8454947 PEG-interferon lambda 1 conjugates |
| 06/04/2013 | CA2702470C Functional lipid constructs |
| 06/04/2013 | CA2532789C Methods and compositions for controlling ectoparasites |
| 06/04/2013 | CA2512820C Long acting insulin for reducing cardiovascular morbidity and mortality in prediabetic patients and patients with type 2 diabetes |
| 06/04/2013 | CA2439178C Template-fixed peptidomimetics with antimicrobial activity |
| 06/04/2013 | CA2432301C Lentiviral vector-mediated gene transfer and uses thereof |
| 06/04/2013 | CA2325735C Hsp70 protein for the treatment of tumours, cancer or infectious diseases through nk-cell activation |
| 06/04/2013 | CA2228667C Antagonists of the oncogenic activity of the protein mdm2, and use thereof in the treatment of cancers |
| 05/30/2013 | WO2013078396A2 Radiation-sterilized biodegradable drug delivery compositions |
| 05/30/2013 | WO2013078286A1 Methods for stimulating hematopoietic recovery by inhibiting tgf beta signaling |
| 05/30/2013 | WO2013078271A1 Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate |
| 05/30/2013 | WO2013078091A1 Collagen mimetic peptides for targeting collagen strands for in vitro and in vivo imaging and therapeutic use |
| 05/30/2013 | WO2013077893A1 Methods and compositions for the treatment of diabetes and related symptoms |
| 05/30/2013 | WO2013077675A1 Method for overcoming tolerance to targeted anti-cancer agent |
| 05/30/2013 | WO2013077641A1 Skin repair enhancer containing growth factors |
| 05/30/2013 | WO2013077617A1 Composition for preventing, treating or alleviating atopic dermatitis comprising immunosuppressant and transglutaminase 2 inhibitor |
| 05/30/2013 | WO2013077534A1 Protein p14 with anti-cancer and anti-allergy activity and pharmaceutical composition comprising the same |
| 05/30/2013 | WO2013077186A1 Activity modulator, medicinal agent comprising same, use of cd300a gene-deficient mouse, and anti-cd300a antibody |
| 05/30/2013 | WO2013076331A1 Phosphorylation on the thr-248 and/or thr-250 residues of transcription factor e2f4 as a therapeutic target in pathological processes associated with somatic polyploidy |
| 05/30/2013 | WO2013076259A2 Polypeptides having lysozyme activity and polynucleotides encoding same |
| 05/30/2013 | WO2013076253A1 Polypeptides having lysozyme activity and polynucleotides encoding same |
| 05/30/2013 | WO2013076183A1 Combination therapy using anti - cd20 antibody and human il-15 |
| 05/30/2013 | WO2013076101A1 Lactoferrin and the white matter |
| 05/30/2013 | WO2013075606A1 Small molecule-polypeptide conjugate inhibiting hiv infection |
| 05/30/2013 | WO2013075600A1 Polyethylene glycol-modified integrin blocker hm-3 and use thereof |
| 05/30/2013 | WO2013075594A1 Artificially designed anti-hiv infection polypeptide, composition and use |
| 05/30/2013 | WO2013075253A1 Thiosulfinate antioxidants and methods of use thereof |
| 05/30/2013 | WO2013075237A1 Mutations of histone proteins associated with proliferative disorders |
| 05/30/2013 | WO2013052498A3 Caspase 9 inhibition and bri2 peptides for treating dementia |
| 05/30/2013 | WO2013034982A3 Immunomodulatory peptides for treatment of progressive neurodegenerative diseases |
| 05/30/2013 | WO2013022262A3 Human resistin receptor, and use thereof |
| 05/30/2013 | WO2012174478A9 Stable formulations of a hyaluronan-degrading enzyme |
| 05/30/2013 | WO2012158962A3 Improved peptide pharmaceuticals |
| 05/30/2013 | WO2012101156A3 Human lactoferrin based peptides having antiinflammatory activity |
| 05/30/2013 | US20130137976 Functional, Cross-Linked Nanostructures for Tandem Optical Imaging and Therapy |
| 05/30/2013 | US20130137763 Fused cyclooctyne compounds and their use in metal-free click reactions |
| 05/30/2013 | US20130137758 Akt activity specifically inhibiting polypeptide |
| 05/30/2013 | US20130137754 Tumor therapy with replication competent sindbis viral vectors |
| 05/30/2013 | US20130137642 Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells |
| 05/30/2013 | US20130137641 Methods for treating pain |
| 05/30/2013 | US20130137639 Stable mia/cd-rap formulation |